{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-299797","form_type":"8-K","ticker":"VOR","cik":"0001817229","company_name":"Vor Biopharma Inc.","filed_at":"2022-12-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.285373+00:00","generated_at":"2026-06-21T08:15:30.085956+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Vor Bio reports initial clinical proof-of-concept for trem-cel; first AML patient engrafts normally","bullets":["First patient received trem-cel dose of 7.6x10^6 CD34+ cells/kg with 88% CD33 editing efficiency.","Neutrophil engraftment at 10 days, platelet recovery Day 22; >90% of PBMCs CD33-negative, 100% donor chimerism.","No infusion reactions or treatment-related adverse events observed post-transplant.","Mylotarg 0.5 mg/m^2 tolerated with no neutropenia or liver enzyme changes through Day 20.","Trial continues enrolling; additional data expected in 2023; conference call Dec 7 at 8am ET."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-299797","json":"https://secwatch.observer/filing/0001193125-22-299797.json","markdown":"https://secwatch.observer/filing/0001193125-22-299797.md","text":"https://secwatch.observer/filing/0001193125-22-299797.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1817229/000119312522299797/0001193125-22-299797-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1817229/000119312522299797/d431519d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T08:15:30.085956+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}